Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SKF101804 Cefixime vs Reference in Healthy Adults
NCT03408392Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cefixime in bacterial infection (2 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Last Time of Quantifiable Concentration at Day 2 and Maximum Observed Plasma Concentration at Day 2. Started Feb 2018; status: completed.
02
Drugs
cefixime
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03408392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408392.